Taub Rebecca

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 18

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 484,162

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.67 to $241.64, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 17

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 484,862

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $239.57 to $240.52, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 16

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 486,505

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-24-000266 · doc4.xml · derivative · entry 25

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,746

Underlying: Common Stock · 18,537 shares

Expires 2026-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F20 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 15

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 458,999

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 14

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 459,099

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.78 to $247.68, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 13

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 459,810

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.52 to $246.50, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 12

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 461,463

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.49 to $245.47, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 11

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 464,197

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.40 to $244.39, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 10

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 464,632

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.38 to $243.35, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 9

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 467,717

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.37 to $242.36, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 8

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 473,336

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.33 to $241.29, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 7

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 477,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-24-000266 · doc4.xml · derivative · entry 24

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,283

Underlying: Common Stock · 27,845 shares

Expires 2026-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F20 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 6

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 458,999

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.12 to $246.70, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 5

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 461,088

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.11 to $246.10, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 4

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 480,005

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.11 to $245.10, inclusive.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 3

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 484,075

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.11 to $244.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 2

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 486,709

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

SEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 486,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-007564 · ownership.xml · derivative · entry 5

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,786

Underlying: Common Stock · 5,786 shares

Expires not disclosed

F5 · derivative.exercise_price: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

F5 · derivative.exercise_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

F5 · derivative.expiration_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

SEC source: 0000950170-24-007564 · ownership.xml · derivative · entry 4

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,718

Underlying: Common Stock · 8,718 shares

Expires 2031-01-23

F4 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000950170-24-007564 · ownership.xml · nonDerivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,787

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.

F2 · balance_after: Represents restricted stock units granted to the Reporting Person on January 16, 2023 and January 23, 2024.

SEC source: 0000950170-24-005296 · ownership.xml · nonDerivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,001

F1 · kind: Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023.

F2 · balance_after: Represents restricted stock units granted to the Reporting Person on January 16, 2023.

SEC source: 0000899243-23-002094 · doc4.xml · nonDerivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,001

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.

F1 · balance_after: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000899243-22-007769 · doc4.xml · derivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,500

Underlying: Common Stock · 61,500 shares

Expires 2032-02-22

F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000899243-21-007758 · doc4.xml · derivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2031-02-22

F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000899243-20-007219 · doc4.xml · derivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2030-03-05

F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2021) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000899243-19-019463 · doc4.xml · derivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · President of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2029-07-10

F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period after such first anniversary, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000899243-19-007019 · doc4.xml · derivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Chief Medical Officer, EVP R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires 2029-03-07

F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 7, 2020) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001179110-18-008426 · edgar.xml · nonDerivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Chief Medical Officer, EVP R&D

10b5-1 filing: Not disclosed

Ownership: Indirect · By SQN, LLC

Disclosed balance after: 655,540

F1 · ownership.nature: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001179110-18-003406 · edgar.xml · derivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Chief Medical Officer, EVP R&D · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 38,000 shares

Expires 2028-03-01

F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 1, 2019) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date.

SEC source: 0001179110-17-003951 · edgar.xml · derivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Chief Medical Officer, EVP R&D · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,300

Underlying: Common Stock · 37,300 shares

Expires 2027-03-02

F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 2, 2018) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues to serve as an officer of the Issuer on each such date.